

Index

For the benefit of digital users, indexed terms that span two pages (e.g., 52–53) may, on occasion, appear on only one of those pages.

Figures are indicated by *f* following the page number

- agent-neutral and agent-relative interests, 212–13, 217–19
- Angell, Marsha, 62–63, 65, 66–67, 68–69, 68n.12, 71, 72
- Aquinas, Thomas, 122, 122n.5
- arbitrary judgments of men, 37–39
- Arendt, Hannah, 117n.1, 125, 125n.8
- Aristotle, 37, 161, 187–88
- Arrow, Kenneth, 295
- Ashcroft, R., 208–9, 210
- autonomy, 56–57, 76–77, 81–82, 84, 97, 99–100, 103–4, 105, 107–9, 242–43, 352
- Barry, Brian, 345, 370, 371
- basic or generic interests, 133–36
 - of community members
 - human development approach on, 379–89, 391–92
 - research and, 158–59, 162–63, 164–65, 166, 172, 251–52
 - egalitarian research imperative and, 149–51, 152, 158–59, 161, 162–63, 165, 249, 337–38
 - integrative approach on, 249, 256–61, 267–69, 288, 408
 - internal constraints on
 - violating, 138–40
 - in just social order, 149–50
 - social institutions and, 150–51
 - special concern for basic interests,
 - principle of equal concern and, 256–59
 - threats to, 136–38
 - uncertainty regarding basic interests, 263–65, 289
- basic or generic interests conception, of
 - common good, 15–16, 25, 118, 148
 - communitarian formulation of, 140–42
 - corporate conception and, 136, 139–40
 - egalitarian research imperative and, 149–50
 - human development approach and, 377
 - institutional utilitarian formulation of, 144–45, 147, 148
 - internal constraints, 138–40
 - justice, space of equality and, 134–36
 - natural law formulation of, 143–44
 - objective consequentialist formulation of, 146–48
 - personal interests and, 131–33
 - political contractarian formulation of, 142–43
 - practical constraint (PC) and, 138, 148–49
 - threats to basic interests in, 136–38
 - triggering condition (TC) and, 138
- Beecher, Henry, 35–36, 39, 46, 47, 191, 304–5, 306, 311–13, 317–18, 336
- Belmont Report*, 10–11, 28, 29, 32, 49, 50, 52, 53–54
 - on beneficence and justice, 53, 54–57
 - on fairness, 55–56, 57
 - on Hippocratic Oath, 181
 - integrative approach and, 289–97
 - on justice, 53, 54–57, 58–59, 60, 352
 - on marginalized groups,
 - recruitment of, 59
 - on research supported by public funds, 58–59
- beneficence, 31–32, 53, 54
 - autonomy and, 56–57, 76–77, 84, 352

- beneficence (*cont.*)
 justice, respect for persons and, 10–11,
 12, 23, 27, 30, 53, 57, 81, 98
 justice and, 53, 54–57, 98
 principle of permissible exploitation
 (PPE) and, 95–96, 97, 99
 research risk and, 289–90
 weak consequentialism and, 97–98
 welfare consequentialist conception
 of, 95–96
- Brandt, Karl, 39–40
- Brink, David, 146–47, 147n.22
- Brody, H., 180, 183, 183n.1
- Centers for Disease Control and
 Prevention, US (CDC), 62, 63
- challenges of measurement, 334–37
- CIOMS *Guidelines*. *See* Council for
 International Organizations of
 Medical Sciences *Guidelines*
- clinical agnosticism, 205–6
- clinical equipoise, 22, 206, 208–11, 212–
 13, 215, 285
 agent-neutral interests of participants
 and, 217–18
 agent-relative interests of individual
 patients and, 219
 duty of care and, 215, 217
 epistemic humility and, 216–17
 Freedman on, 21, 178, 214, 219, 221,
 250, 265
 IRBs and, 218
 particularities of individual patients
 and, 217–20
 uncertainty regarding basic interests
 and, 265
- clinical equivalence, 205–6
- clinical judgment principle, 213–14, 215–
 16, 266
- clinical medicine, 179, 180, 183–84
- clinical research, 176–77, 180, 183–85,
 201–4, 292
- clinician-patient relationship, 181–83, 198
- clinicians, 9, 19, 67–69, 176–77, 179, 182
- collaborative partnership, 349, 350, 351,
 352, 353–59, 365, 366–67, 368, 396
- colonialism and post-colonialism,
 343, 393–95
- common good, 6–7, 43–44, 120n.2,
 388. *See also* basic or generic
 interests conception, of common
 good; corporate conception, of
 common good
- community members and, 23–24, 131,
 139, 142
- diseases and illnesses as threats to,
 122, 138
- diversity, spurious consensus
 and, 128–29
- division of social labor and, 138–39
- egalitarian research imperative and,
 19, 21, 23–24, 118, 161, 164, 165–
 66, 249
- individual good and, 5–6, 31–
 32, 139–40
- individual interests and, 120, 121–24,
 128–29, 139–40, 145
- individual rights and, 30, 42, 123, 138
- Jonas on, 122–23, 129–30, 148
- justice and, 153, 158, 253–55
- just political order in, 134–35
- just social order and, 15–18, 30, 31–32
- larger social purposes and, 12
- lenient triggering condition (TC)
 and, 125–27
- local de jure standard of care and, 376
- medical research and, 109–10, 139
- normative claim (NC) and, 120, 121–22,
 123, 124, 126, 128, 136, 253–55
- orthodox research ethics and, 43–44, 88
- parochial interests subordinated
 to, 333–34
- practical constraint (PC) and, 120, 121,
 123–24, 126–27, 128, 254
- pragmatic value of, 118–19
- private sector research and, 166
- research and, 20–21, 41–42, 403
- research imperative and, 87–88
- research risks and, 293
- social imperative and, 88, 117, 148,
 172–73, 175
- strict triggering condition and, 124
- structure of appeals to, 118–21
- triggering condition (TC) and, 120, 121,
 123, 124, 125–27, 128, 129, 131,
 138, 253–55

- communitarian formulation, of basic or generic interests conception, of common good, 140–42
- community, 34–35, 40–41, 123, 127, 140, 141, 161. *See also* human development approach, to international research
- basic social systems and structures of, 118, 297–98, 372–73, 375–76, 379–82, 386–89, 417
- rights to social and medical progress, 38–39
- welfare of, 123, 125, 126, 129–30
- community members, 3–4, 320
- basic interests of, research and, 158–59, 162–63, 164–65, 166, 172, 251–52
- common good and, 23–24, 131, 139, 142
- as equals, 150
- equity of, 151, 152
- as free and equal, 118, 162
- health systems and, 158–59
- individual rights and, 140, 141
- local de jure standard of care and, 415
- medical care and public health services for, 150
- social imperative of research for, 118
- social institutions and, 17, 30, 150–53, 162–63, 165, 166, 380–81
- welfare of, 129–30
- component analysis, 223–24, 283–89, 290
- concern for welfare, 195, 250–51, 266–69, 272–73, 279–80
- conflicting judgments, self-defeating requirements and, 204–8
- consequentialism, 55, 106n.15, 126, 144
- patient-centered, 181–83, 184, 186, 188–89, 228
- utilitarian, 184, 191
- weak, 97–98, 107
- welfare, 95–96, 100, 100n.13, 105n.14, 105–6, 107
- contract research organizations (CROs), 112, 361, 362
- cooperative resentment, paradox of, 328–34
- coordination game, for study participants, in medical research, 238–39, 239f, 240f
- coordination problems, 20, 22–23, 179, 239–41, 300–1, 309–10, 327–29, 333–34
- corporate conception, of common good, 117, 118, 121–29, 148, 175
- basic or generic interests conception and, 136, 139–40
- diversity and spurious consensus, 128–29
- interests distinct from individuals in, 121–24
- lenient triggering condition (TC) in, 125–27
- problems with, 129–31
- strict triggering condition (TC) in, 124
- Council for International Organizations of Medical Sciences *Guidelines* (CIOMS *Guidelines*), 60, 77–78, 397
- CROs. *See* contract research organizations
- Declaration of Helsinki (DoH)*, 37, 38, 47, 49, 60, 61–63, 64, 65n.11, 66, 75, 77, 78n.13, 181
- demandingness, 87, 95, 101, 107–8
- dilemma of determinate duties, 241–42, 288
- division of social labor, 9, 10–11, 12, 15, 17, 30, 59, 109, 118, 161, 252, 415
- common good and, 138–39
- egalitarian research imperative and, 153, 159–60, 162, 163, 165–66, 297
- human development approach on, 377
- just, 252, 258
- mechanism design and, 163
- private research enterprises in, 166
- social institutions in, 381, 384
- DoH. *See* Declaration of Helsinki
- drug approval, 167–68, 169–70
- drug development, 154–56, 157, 163, 168–72, 403–4
- duty of care, 65, 66–67, 211, 212–20
- autonomy, independent content and, 242–43
- clinical equipoise and, 215, 217
- fiduciary, 9, 179, 182, 221, 229, 231–32

- duty of personal care, 177–78, 181, 192–93, 197–98, 199–200, 201–2, 206–7, 213–14, 215, 250–51
 cosmetic procedures and, 230
 dilemma of determinate duties and, 241–42
 Hippocratic, 228, 229–30, 231–32, 241–42, 288
 purely research-related risks and, 223–24
- egalitarian research imperative, 18–19, 21, 22, 23, 173, 244, 249
 basic interests conception of common good and, 149–50
 basic or generic interests and, 149–51, 152, 158–59, 161, 162–63, 165, 249, 337–38
 common good and, 19, 21, 23–24, 118, 161, 164, 165–66, 249
 on community members as free and equal, 118, 162
 corporate conception of common good *versus*, 175
 diversity and, 179–80
 division of social labor and, 153, 159–60, 162, 163, 165–66, 297
 as egalitarian in two respects, 159–61
 on governments, 162–64
 grounding, 149–54
 human development approach and, 24, 25, 344, 375, 377, 391–96, 419
 integrative approach and, 249, 251, 252, 253, 285, 297
 international research and, 375
 IRB review and, 299, 323
 justice and, 153–54, 164
 just social order and, 164–65
 on knowledge produced by research, as public good, 154–59, 161
 paradox of cooperative resentment and, 332–34
 principle of equal concern and, 250
 prior moral claims and, 164–67
 prospective review and, 323
 requirements of, 250–55, 301, 344
 on research
 knowledge and, 152, 153, 154–59
 oversight, 301, 309, 323
 participants, 152, 164
 risks, 176
 as scheme of cooperation, 162–67, 299–300
 as scheme of social cooperation, 18, 19, 149, 161, 162, 165–66
 social imperative for, 149
 on social institutions, 149–53
 social systems and, 158–59, 161, 247
 social value requirement in, 251–52
- Eisenberg, Leon, 32–35, 38–39, 42, 43–45, 60, 78, 126
- equality, 55, 134–36, 370–72
 moral, 108–9, 135–36, 152, 260, 301, 318, 365, 391–92
- equal respect, 107–10, 159–60, 176, 180, 366, 378–79
- equipoise, 63, 67–69, 68n.12, 76, 197–200, 208–11. *See also* clinical equipoise
 collective or professional, 210
 Fried on, clinical equipoise and, 214
 orthodox research ethics and, 178
 template for the appeal to uncertainty and, 200–4
 theoretical, 209, 210–11
 uncertainty and, 177–78, 204–5, 206–7, 208–10, 211, 215, 226
- equity, 151, 152, 168, 400
- fair benefits approach, to international research, 12–13, 92, 345
 benchmarks for fairness, 359–62
 collaborative partnership in, 349, 350, 351, 352, 353–59, 365, 366–67, 368, 396
 consistency problems in, 351–53
 exploitation, as unfair level of benefit, 346–47
 imperfect procedural justice in, 362–64
 independent check on fairness, 362–65
 minimalist approach to justice and, 370–73
 models, empirical assumptions and, 367–69
 principle of transparency, 350–51, 352, 362

- procedural alternative and, 346–53
 pure procedural justice in, 362–64, 365–67
 as race to the bottom, 361–62
 standards of fairness, 347–49
 study participant benefits in, 359–61
- fair division of moral labor, providing
 assistance for, 109–10
- fairness, 55–56, 57, 369, 379–80
 independent check on, fair benefits
 approach and, 362–65
 justice and, 3–4, 16, 23, 84–85, 90, 91,
 113, 352, 369
- fixed randomization allocation (FRA),
 270, 272, 280
- free and equal persons, 16–17, 18–19,
 159, 175
 in just social order, 135
 medical progress and, 45
 National Commission, on study
 participants as, 309
 principle of equal concern and, 20–21
 prospective review and, 323
 scheme of cooperation among, 162–67
 study participants as, 23, 252–53,
 254, 291, 293, 300–1, 309, 323,
 376, 378–79
- Freedman, Benjamin, 21, 178, 201, 204,
 206–7, 209–10, 211, 212–13, 214,
 219, 220, 221, 250, 265, 268
- freedom from arbitrary interference,
 176, 307–8
- Fried, Charles, 177–78, 197–98, 209, 211,
 213–14, 219
- global de jure standard of care, 66, 67–68,
 69–71, 72–73, 74, 409, 410–
 16, 417–18
- Hardin, Russel, 144, 145, 148
 Harris, John, 44–45, 125n.7
- HDC-ABMT. *See* high-dose
 chemotherapy with autologous
 bone marrow transplant
- health systems, 17–18, 71, 75, 172
 community members and, 158–59
 drug development and, 168–69
 global de jure standard of care and, 70–71
 HIC, 66–67, 78–79, 396, 412
 host community, CIOMS *Guidelines*
 on, 397
 in human development approach, 384–85
 learning, 22, 274, 276–82
 LMIC, 70, 79–80, 385–86, 397–98,
 401, 404–6
 medical information and, 156, 157
 minority populations underserved
 by, 168
 standards of care in, 66–67, 75, 414
 universal access to medical care and, 58
- Heyd, David, 225–26, 235–36
- HICs. *See* high-income countries
- high-dose chemotherapy with autologous
 bone marrow transplant (HDC-
 ABMT), 265, 266–69
- high-income countries (HICs), 11–12,
 13, 24–25, 27, 43, 370–71. *See also*
 low- or middle-income countries
 (LMICs), HICs and
 domestic research in, 75–76
 health systems, 66–67, 78–79, 396, 412
 human development in, 391
 PPE and, 94
 standard of care in, 66–67, 72–73, 75,
 411, 412–13, 414
- Hippocratic clinician, 188–89, 228
- Hippocratic duty, 189, 190, 201–2, 226,
 228, 229–30, 231–32, 241–42, 288
- Hippocratic medicine, 28, 49
- Hippocratic Oath and ethics, 181–82
- Hippocratic patient-centered
 consequentialism, 181–83,
 184, 228
- HIV/AIDS, 382–83
- HIV transmission, perinatal, 62–64, 65,
 66, 67, 68–69, 76–77, 412, 421
- human development approach, to
 international research, 23–25,
 153
 on basic interests and moral claims on
 basic social institutions, 379–89
 basic or generic interests conception of
 common good and, 377
 on communities and community
 members, 392–93, 399, 402–
 7, 420–21
 basic interests of, 379–89, 391–92

- human development approach, to international research (*cont.*)
- basic social systems and structures of, 375–76, 379–83, 386–89, 392, 395–96, 402–3
 - full coverage to moral claims, 384–86
 - in LMICs, 377, 378, 379, 385, 392–96, 397–98, 399–400
 - duty to promote human development, 389–407
 - egalitarian research imperative and, 24, 25, 344, 375, 377, 391–96, 419
 - HICs, LMICs and, 376–77, 389, 394, 396, 405–6, 407
 - on IRBs, 390, 398–99
 - on justice and basic social structures, 379–81
 - on local de jure standard of care, 376, 378–79, 407–9
 - misaligned research, injustice and, 402–7
 - overview of, 376–79
 - on reasonable availability, 378, 379, 397–402, 404, 407
 - responsiveness and reasonable availability, as system-level concerns, 397–402
 - responsiveness requirement in, 378, 379, 397–402
 - social determinants of health, prior moral claims and, 381–83
 - standard of care in, 24–25, 407–16
 - on study participants, as free and equal persons, 378–79
- human rights, 39–41, 42
- individual goods, 5–6, 31–32, 39, 122, 139–40
- individual interests, 135, 175. *See also*
- basic or generic interests
 - common good and, 120, 121–24, 128–29, 139–40, 145
 - community interests and welfare and, 34–35, 40–41, 125
 - personal life plans and, 132–33, 136–37
 - risks of study participation and, 235–36, 235n.8
- individual rights, 30, 38, 39, 42, 120, 121, 123, 127, 138, 140, 141, 175, 228–32
- individuals, 37, 40–45, 54, 120, 121, 135–37, 159, 179
- individual uncertainty, fragility of, 200–2, 204
- individual virtue, strategic environment and, 336–37
- individual welfare, 9, 20, 41, 55, 105, 125–26, 127, 129, 130, 144, 179, 244
- informed consent, 7, 14, 52, 53–54, 101–4, 171, 307, 308
- institutional design, 110–11, 112–13, 369, 401
- Institutional Review Board (IRB), 7, 12, 29, 30, 46, 51, 169–70, 212–13, 320, 389–90
- clinical equipoise and, 218
 - critics of, 330–31, 330nn.12–13, 337
 - egalitarian research imperative and, 299, 323
 - human development approach on, 390, 398–99
 - paternalism and, 323, 329
 - prospective review by, 328, 334–35
 - protectionism of, 52, 329
 - RCT approved by, 214
 - research oversight and, 339–40
 - review process, improving, 321
 - risk of delay, incentives and, 321–23
 - on social value, of research, 327–28
 - on study protocols, 214, 242, 334–35, 336, 398–99
- institutional utilitarian formulation, of basic or generic interests
- conception, of common good, 144–45, 147, 148
- integrative approach, to risk assessment and management, 19–22, 25, 139–40
- alternative frameworks *versus*, 282–97
 - appeals to uncertainty and component analysis, 283–89
 - Belmont approach, 289–97
 - criteria for evaluating, 282–83
 - on basic or generic interests, of study participants, 249, 256–61, 267–69, 288, 408
 - on concern for welfare, 266–69, 279–80
 - criteria for admissibility in, 268–69, 281
 - egalitarian research imperative and, 249, 251, 252, 285, 297

- HDC-ABMT example, 265, 266–69
 on justice and common good, 253–55
 learning health system and, 276–82
 principle of equal concern in, 252–53, 254, 255–63, 266–69, 279–80, 407
 principle of no impermissible gambles in, 273, 279–80
 on public purpose of research, justice and, 251
 RAR in, 269–71, 272–74, 276–77, 278, 280
 rational expectation in, 272–73
 reasonable diversity in, 276–79, 281–82
 social consistency in, 259–63
 social model of learning, uncertainty, and disagreement in, 269–76
 social value in, 252–53, 266–69, 279–80, 289, 296, 297
 social value requirement in, 268–69, 276–77, 285, 290–91, 408
 special concern for basic interests in, 256–59
 uncertainty, as practical test within, 263–69
 uncertainty regarding basic interests in, 263–65
 unnecessary risks prohibited, 255–56, 259
- intellectual property, 58–59, 83, 153, 156, 165, 166–67, 387–88, 394–95
- International Ethical Guidelines for Biomedical Research Involving Human Subjects, CIOMS, 60, 77–78, 397
- international research, 11–12, 13, 23, 71, 76, 77, 79, 375. *See also* fair benefits approach, to international research; human development approach, to international research
- CROs in, 112
- domestic research conducted in LMICs and, 71–75
- ethical fault lines stressed by, 60–84
- justice and, 23–25
- minimalist approach to justice and, 81–84
- PPE and, 112
- standard of care in, 24–25, 30–31, 64–67
- Surfaxin case, 78–80
- zidovudine short-course controversy, 60–84
- IRB. *See* Institutional Review Board
- IRB triangle, 7–9, 13, 23, 30, 45, 51, 53, 57–58, 59, 71, 88, 164, 169, 172, 343–44, 352
- Jewish Chronic Disease Hospital (JCDH), 6–7, 46–47, 49–50
- Jonas, Hans, 6–7, 30, 41–42, 43–44, 45–, 88, 114, 117, 118, 124–25nn.6–7
 on common good, 122–23, 129–30, 130n.13, 148
 on individual rights and welfare, 127
 on NC, 122
 on strict triggering condition (TC), 124
- justice, 8–9, 101
 basic social structures and, 379–81
Belmont Report on, 53, 54–57, 58–59, 60
 beneficence, respect for persons and, 10–11, 12, 23, 27, 30, 53, 57, 81, 98
 beneficence and, 53, 54–57, 98
 in CIOMS *Guidelines*, 77
 common good and, 153, 158, 253–55
 contractarian theory of, 142
 egalitarian research imperative and, 153–54, 164
 equity and, 168
 fairness and, 3–4, 16, 23, 84–85, 90, 91, 113, 352, 369
 governments and, 164
 health systems and, 71
 HICs, LMICs and, 343, 375
 human development approach to international research and, 23–25, 379–81
 human development process and, 416–22
 human nature and, 142
 imperfect procedural, 362–64
 IRB triangle and, 57–58, 59, 343, 344, 352
 minimalist approach to, 12, 56–57, 81–84, 82n.16, 352, 370–73, 418–19
 morally relevant information and, 372–73
 as mutual advantage, 345, 370
 mutually beneficial agreements and, 12–15

- justice (*cont.*)
 neglect of, consequences of, 53–56
 protectionism and, 59
 public purpose of research and, 251
 pure procedural, 362–64, 365–67
 Rawls on, 10–11, 53
 social, 55, 59, 345, 398–99, 400
 social institutions and, 10–12, 30, 71, 372, 375
 space of equality and, 134–36
 without social institutions, 10–12, 30, 71
- just social order, 15–18, 30, 31–32, 45, 75–76, 78, 83–84, 135, 141, 149–50, 164–65, 328, 337–39, 344, 418–22
- just society, 71, 136, 150, 191–92, 193–94
- just state, 41, 141, 161
- knowledge, 50–51, 154–56, 162–63, 176–77
 produced by research, as public good, 104–5, 154–59, 161, 164–65, 166–67
- knowledge production, systems of, 23–24, 59, 247, 378
- Kukla, R., 68n.12, 75–76, 158–59, 160n.24
- larger social purposes, 5–6, 7, 12, 14–15, 27, 29–30, 31–41, 422
 orthodox research ethics and, 83–84, 100, 164, 172
 research severed from, 44, 45, 51, 53, 78, 333
- Lasagna, Louis, 39, 123–24, 336
- learning health system, 22, 274, 276–82
- lemons problem, 22–23, 301, 323–28
- LMICs. *See* low- or middle-income countries
- local de facto standard of care, 66, 74, 409–10, 417
- local de jure standard of care, 67, 75–76, 376, 378–79, 407–9, 412–13, 415, 417–18
- low- or middle-income countries (LMICs), 11–12, 13, 14–15, 24–25, 27, 63–64, 389–90
 autonomy of populations, international medical research and, 81–82
 domestic research conducted in, 71–75
 drug prices and, 394–95
 health needs, 371–72, 382, 385–86
 health systems, 70, 79–80, 385–86, 397–98, 401, 404–6
 human development approach, on communities in, 377, 378, 379, 385, 392–96, 397–98, 399–400, 405
 IRB triangle and, 344
 perinatal HIV transmission, short-course trials and, 63–64, 66, 67, 76–77, 421
 public goods of research and, 345–46
 social institutions in, 376, 378, 403
 social structures of, 395–96, 402, 414
 standard of care in, 66–67, 70, 72, 74–75, 414, 420
 Surfaxin in, 79–80
- low- or middle-income countries (LMICs), HICs and
 clinical trials and research sponsored by, conducted in, 90–91, 110, 112, 343
 double standard, of international research in, 74–75
 fair benefits approach and, 346, 352–53, 362, 368–69
 human development approach and, 376–77, 389, 394, 396, 405–6, 407
 justice and, 343, 375
- Luce, Duncan, 295
- Marquis, D., 200–1
- Mbidde, Edward K., 72, 73, 74–75
- McDermott, Walsh, 5–6, 35, 36–39, 41, 42, 43–45, 114, 120, 123–24, 176, 302–3
- mechanism design, 7–8, 163, 333, 345
- medical care, 9, 49–50, 58, 150
- medical paternalism, 102–3, 179, 230–31, 234, 243
- medical progress, 38–39, 45
- medical research, 5–6, 32, 33, 34, 37–39, 43, 45, 49–50, 60
 common good and, 109–10, 139
 DoH on, 37, 61–62, 77, 78n.13
 playing God and, 35–36
 medicine, incompleteness of, 188–90

- Menikoff, J., 225, 232, 235–36
- Miller, F. G., 180, 183, 183n.1
- Miller, Paul, 197–98, 212–15, 216, 217–19, 264
- minimalist approach, to justice, 12, 56–57, 81–84, 82n.16, 352, 370–73, 418–19
- moral autonomy, 99–100, 103–4, 105
- moral equality, 108–9, 135–36, 152, 260, 301, 318, 365, 391–92
- moral freedom, 135, 159
- mutually beneficial agreements, 12–15, 32, 346, 350
- National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 28–29, 33, 34, 49, 52, 53–54, 289, 301, 302, 312–13, 319
- coordination problems and, 328–29
- on informed consent, 53–54, 307, 308
- protectionism and paternalism of, 328
- reforms by, 302, 303, 307–9
- National Institutes of Health, US (NIH), 62, 63, 72, 302
- natural law formulation, of basic or generic interests conception, of common good, 143–44
- Nazi doctors and scientists, 39–40, 47, 49, 122, 303
- NC. *See* normative claim
- New England Journal of Medicine (NEJM)*, 35–36, 62–63, 72, 73
- NIH. *See* National Institutes of Health, US
- non-exploitation approach, 290–92
- normative claim (NC), 120, 121–22, 123, 124, 126, 128, 136, 159, 253–55
- norms of respect, 89–90, 91, 92–94, 95, 100, 101, 102, 105–6
- Nuremberg Military Tribunals and Nuremberg Code, 39–40, 47, 49, 53–54, 122, 303
- objective utilitarianism, 146–47, 147n.22
- orthodox research ethics
- common good and, 43–44, 88, 117
- conceptual ecosystem of, 4, 5
- equipoise and, 178
- foundations of, tensions at, 3–4
- integrative approach and, 252
- IRB triangle and, 169, 172
- justice and beneficence and, 98
- just social order and, 76, 83–84, 328
- larger social purposes and, 83–84, 100, 164, 172
- local de jure standard of care in, 75–76, 408–9
- parochialism of, 13, 31, 66, 109, 118, 167, 170, 372
- paternalism in, 10, 14, 52, 97, 172, 300, 301
- PPE and, 89, 94, 95, 96, 97, 99, 100–1, 105, 108–10, 113–14, 160–61
- problematic commitments shaping conceptual ecosystem of, 27, 176, 297–98
- inherent dilemma, 5–6, 30
- international research, 30–31
- justice reduced to mutually beneficial agreements, 12–15
- justice without social institutions, 10–12, 30, 71
- paternalistic foundations, 10, 30
- research as functional role, 8–9
- social imperative, private transaction and, 6–7
- two dogmas of research ethics, 9, 178, 179–80
- two main stakeholders, 7–8
- protectionism of, 88–89, 331–32
- researcher-participant relationship in, 111, 164, 269–70
- on research oversight, 300, 301
- on study participants, 164, 168, 169, 170–71, 329
- on study protocols, 171
- Wertheimer on core commitments of, 14–15
- Parfit, D., 125–26, 127n.9
- parochialism, 7, 8, 13, 27–31, 72, 333–34
- of orthodox research ethics, 13, 31, 66, 109, 118, 167, 170, 372
- Pasteur, Louis, 32–33

- paternalism, 52, 81–82, 103, 323
 medical, 102–3, 179, 230–31, 234, 243
 in orthodox research ethics, 10, 14, 52,
 97, 172, 300, 301
 protectionism and, 97, 328, 329
 research oversight and, 299,
 301, 337–38
 of responsiveness and reasonable
 availability requirements, 84
- patient-centered consequentialism, 181–
 83, 184, 186, 188–89, 228
- patients, 19, 49–50, 157, 168–69, 217–20
- PC. *See* practical constraint
- personal interests and life plans, 132–33,
 135–38, 139, 141, 142–44, 150,
 161, 179–80, 228–41, 247, 249,
 258, 293–94
- Petryna, Adriana, 403–4
- PHS. *See* Public Health Service
- placebo controls, in clinical trials, 61–63,
 64, 65, 68–70, 71, 72–74, 79, 80, 81,
 91, 313–14
- political contractarian formulation,
 of basic or generic interests
 conception, of common
 good, 142–43
- PPE. *See* principle of permissible
 exploitation
- practical constraint (PC), 120, 121, 123–
 24, 159–60, 254
 in basic or generic interests conception,
 of common good, 138, 148–49
 weak, 124, 126–27, 128
- principle of equal concern, 20–22, 23,
 249–50, 254, 255–63, 266–69, 272,
 279–80, 378–79, 407–9, 410, 412–
 13, 414–16
- principle of no impermissible gambles,
 273, 279–80
- principle of permissible exploitation (PPE)
 autonomy, integrity of life and, 107–9
 autonomy and, 97, 104, 105, 107–9
 beneficence and, 95–96, 97, 99
 conceptual foundations of orthodox
 research ethics and, 113–14
 consent and, 101–2, 106
 (un)equal respect, 107–10
 fair benefits view *versus*, 92
 fair division of moral labor, 109–10
 on harm proviso, violating, 110–13
 HICs and, 94
 impartial version of, 103–6, 106n.15
 on informed consent, 101–4
 institutional design and, 111, 112–13
 international research and, 112
 on moral autonomy, 104, 105
 norms of respect and, 89–90, 92–94, 95,
 100, 101, 102, 105–6
 options, private sphere and, 97–100
 orthodox research ethics and, 89, 94,
 95, 96, 97, 99, 100–1, 105, 108–10,
 113–14, 160–61
 participant-centered version of, 102–3
 on researchers and participants, 110
 on respect for autonomy, 97
 respect for persons and, 96–97, 103
 on responsiveness and reasonable
 availability, 91–92
 standard of care and, 91
 targets of, 89–92
 on violations of respect, permissibility
 of, 93–97, 96n.6, 100, 101, 102,
 106–7, 110
 weak consequentialism and, 107
 on welfare, 95–97, 101, 102, 103, 105,
 106, 110
 welfare consequentialism and, 95–
 96, 105–6
 Wertheimer on, 88–89, 92, 160, 331–32,
 346–47, 369
 wrongdoing justified by, 101
- principle of proportionality, 245,
 246, 263
- principle of transparency, 350–51,
 352, 362
- principle of utility, 246–47
- prisoner's dilemma, 20, 179, 220–21, 225–
 27, 236–41, 237f, 239f, 240f
- private research enterprises, 163, 166–67
- private transactions, 6–7, 41–45, 111
- proportionality, principle of, 245
- prospective review, benefits of, 319–23
 asymmetries between ex ante and ex
 post perspectives eliminated
 by, 319–21
 check on self-serving assessments, 321

- coordination problems of unregulated systems resolved by, 333
- IRBs and, 328, 334–35
- quality assurance, 327–28
- risk of delay changes incentives, 321–23
- social perspective on, 332–33
- protectionism, 38, 42, 45, 302
 - of IRBs, 52, 329
 - neglect and, 59–60
 - of orthodox research ethics, 88–89, 331–32
 - paternalism and, 97, 328, 329
 - of prospective review, 323
- public goods
 - knowledge produced by research as, 104–5, 154–59, 161, 164–65, 166–67
 - moral transgressions for sake of, 32
 - research producing, 104–5, 154–59, 161, 164–65, 166–67, 175, 323, 345–46
 - social goods and, 17–18
 - social systems and, 247
 - study participants and, 247
 - unique, 17–18, 337–40
- Public Health Service (PHS), 48–49, 302, 321
- purely research-related risks, 285
 - clinician-centered formulation, of argument from, 221–23, 226, 227n.7, 227–28
 - duty of personal care and, 223–24
 - participant-centered formulation, of argument from, 224–25, 226, 227n.7
 - prisoner's dilemma and, 225–27
 - uncertainty and, 220–21, 222–23
- pure procedural justice, 362–64, 365–67
- Ramsey, Paul, 32
- randomized clinical trials (RCTs), 62–63, 67–68, 69, 72, 79, 80, 81, 91, 214, 265, 410
 - FRA, 270, 272, 280
 - randomization weights, 272, 274–75, 278, 279–80
 - RAR, 269–71, 272–74, 276–77, 278, 280–81
 - RCTs, 212, 214, 225–26, 266–67
 - RAR. *See* responsive adaptive randomization
 - rational expectation, 272–73
 - Rawls, John, 10–11, 53, 127, 133, 142–43, 147n.22, 147–48, 150, 384
 - RCTs. *See* randomized clinical trials
 - reasonable availability
 - in human development approach, 378, 379, 397–402, 404, 407
 - responsiveness and, 76–78, 82–84, 90–92, 379, 389–90, 397–402
 - reasonable diversity, of conscientious and informed experts, 276–79, 281–82
 - REB. *See* Research Ethics Board
 - REC. *See* Research Ethics Committee
 - Reed, Walter, 37–38
 - regulations, 6, 7, 60, 153, 163, 165, 261, 302, 334–35, 375–76. *See also* research oversight
 - research, 6–7, 34–35
 - basic interests, of community members and, 158–59, 162–63, 164–65, 166, 172
 - basic social structures and, human development approach on, 386–89
 - with children, 32
 - CIOMS *Guidelines* on, 77–78
 - common good severed from, 41–42
 - functional characterization of, 46–52, 53
 - as functional role, 8–9
 - generalizable knowledge from, 50–51, 176–77
 - with human participants, dilemma at heart of, 175–80, 186
 - incompleteness of, 191–92
 - just social order and, 75–76, 78, 337–39, 344, 418–22
 - lemons problem in, 325–27
 - as optional goal, 42–44
 - as progressive undertaking, 31–35
 - public goods produced by, 104–5, 154–59, 161, 164–65, 166–67, 175, 323
 - public purpose of, social value and, 250–52
 - public support for researchers, tipping point of, 317–19

- research (*cont.*)
 as scheme of social cooperation, 3–4,
 15, 17, 18, 19, 149, 161, 162,
 165–66, 172, 252, 253, 299–301,
 302, 375–76
 social imperatives for, 41–42, 60, 114,
 118, 149, 154, 175
 as social practice, democratizing and
 legitimating, 302–9
 tragedy of the commons and, 310–
 13, 315–19
 treatment and, 49–52, 58–59
 as utilitarian, 176–77, 183–85, 191–93,
 201–2, 289
- researchers and participants, 7, 51, 100,
 110, 111, 164, 254, 269–70, 325–27
- research ethics. *See also* orthodox
 research ethics
 abuses and scandals, in emergence of,
 6–7, 28, 32, 46, 52
 community members and, 3–4
 justice, as last virtue of, 53–60
 moral pitfalls to navigate in, 14–
 15, 87–89
 National Commission and *Belmont
 Report*, in emergence of, 28–30
 non-paternalistic, 22–23
 norms of, 49–50
 philosophical foundations of, 3–5
 practical influences on, 46
 protectionist view of, 38, 45, 52
 on risks to participants and benefits to
 others, 103
- Research Ethics Board (REB), 7, 29
- Research Ethics Committee (REC),
 7, 29, 76
- research imperative, 32, 35, 43n.6, 44,
 45, 87–88, 103, 117. *See also*
 egalitarian research imperative
- research oversight, 6, 299, 300, 301, 309,
 312–13, 323, 334–35, 337–38. *See
 also* Institutional Review Board
- prospective review and, 319–23
 of wider range of stakeholders, 339–40
- research participants, 14, 20, 52, 103,
 139n.19, 152, 164, 171, 175, 178–
 79, 300–1, 302–3, 323. *See also*
 study participants
- research participation, 20–21, 225–27,
 236–41, 254, 302–3, 323
- research risk, 5, 176, 242–43, 244, 263, 288,
 289–90, 293–94, 313, 314–15. *See
 also* purely research-related risks
- respect
 equal, 107–10, 159–60, 176, 180,
 366, 378–79
 norms of, 89–90, 91, 92–94, 95, 100,
 101, 102, 105–6
 violations of, justification for
 permitting, 93–97, 96n.6, 100, 101,
 102, 106–7, 110
- respect for persons
Belmont Report on, 10–11, 53–54, 56–57
 beneficence, justice and, 10–11, 12, 23,
 27, 30, 53, 57, 81, 98
 in non-exploitation approach, 291, 292
 PPE and, 96–97, 103
- responsive adaptive randomization
 (RAR), 269–71, 272–74, 276–77,
 278, 280
- responsiveness, reasonable availability
 and, 76–78, 82–84, 90–92, 379,
 389–90, 397–402
- responsiveness requirement, 77, 78, 94,
 378, 401, 406
- Richards, E. P., 225, 232, 235–36
- risk-benefit analysis, 250, 290
- risks. *See also* integrative approach, to
 risk assessment and management;
 purely research-related risks;
 uncertainty
 benefits and, 185–86, 232, 234, 244, 250,
 290, 293–94, 300–1, 315–17, 322
 net-risk approach, 290–91
 personal, as not irrational, 232–36
 principle of proportionality on, 245, 263
 purely research-related, 220–27
 reasonable, 185–86, 223–24
 to research participants, 175, 178–79,
 300–1, 323
 unnecessary, inadequate social value
 and, 305–7
- role-related obligations, of clinicians and
 medical professionals, 9, 67–69,
 71, 180, 184, 186, 224–25
- rule of law, 37, 176, 297

- sanctioning neglect, 14–15, 87–88, 101
 sanctioning wrongdoing, 14–15, 87–88
 Thatcher, David, 63, 72
 scientific progress, 42, 45, 201, 294, 305, 307, 312
 self-defeating requirements, conflicting judgments and, 204–8
 Sen, Amartya, 382, 392n.7
 senseless studies, permitting, 202–4
 senses of incompleteness, 186–88
 separateness of persons, 127, 127n.9
 Servatius, Robert, 40, 42
 Shalala, Donna, 125n.7
 short-course clinical trials, 60–84, 420
 Shue, Henry, 381, 384
 Sidgwick, H., 127n.9, 146
 social authority, 302–5, 307–9, 373, 388–89
 social goods, 17–18, 34–35, 38, 39, 122
 social imperatives, 30, 41–42, 60, 114, 118, 149, 151, 154, 161, 175
 common good and, 88, 117, 148, 172–73, 175
 private transactions and, 6–7, 41–45
 social institutions
 community members and, 17, 30, 150–53, 162–63, 165, 380–81
 in division of social labor, 381, 384
 egalitarian research imperative on, 149–53
 health systems and, 384–85
 human development approach, on basic interests and, 379–89
 justice and, 10–12, 30, 71, 372, 375
 in LMICs, 376, 378, 403
 moral claims on, 379–89
 reconnecting to, 16–17
 research enterprise and, 387–88
 social justice, 55, 59, 345, 398–99, 400
 social model, of learning, uncertainty, and disagreement, 269–76
 social systems and structures, 158–59, 161, 166, 247, 300, 372–73, 375–76, 379–83, 386–89, 392, 395–96, 402–3, 414, 417, 422. *See also* health systems
 social value, 34, 250–52, 254, 305–7, 327–28
 equal concern and, 21–22, 249–50, 407–9
 in integrative approach, 252–53, 266–69, 279–80, 289, 296, 297, 408
 social value requirement, 195, 251–52, 268–69, 276–77, 285, 290–91, 408, 413, 414
 stag hunt, 20, 240f, 240, 300–1, 323, 330
 standard of care
 global de jure, 66, 67–68, 69–71, 72–73, 74, 409, 410–16, 417–18
 in HICs, 66–67, 72–73, 75, 411, 412–13, 414
 in human development approach, 24–25, 407–16
 in international research, 24–25, 30–31, 64–67
 just moral baselines and, 416–18
 in LMICs, 66–67, 70, 74–75, 414, 420
 local and global reference points of, 64–67
 local de facto, 66, 74, 409–10, 417
 local de jure, 67, 75, 376, 378–79, 407–9, 412–13, 415, 417–18
 PPE and, 91
 responsiveness, reasonable availability and, 90–92
 for study participants, 30–31, 75
 strategic environment, 7–8, 163, 166, 300, 304–5, 307, 309, 334–35, 336–37, 345–46, 398, 402
 study participants, 10
 access to care, 74
 agent-neutral and agent-relative interests of, 217
 basic interests of, integrative approach on, 249, 256–61
 from captive populations, 302–4
 clinical equipoise and, 21
 coordination game for, 238–39, 239f, 240f
 deaths of, benefits to society and, 38
 as free and equal persons, 23, 252–53, 254, 291, 300–1, 309, 376, 378–79
 in IRB triangle, 88, 164
 moral dilemma for clinicians and, 19
 non-exploitation approach on, 290–92

- study participants (*cont.*)
 orthodox research ethics on, 164, 168, 169, 170–71, 329
 PPE and, 91
 principle of equal concern and, 20–21, 378–79
 protections for, 33–34
 public goods and, 247
 researchers and, 7, 51, 100, 110, 111, 164, 254, 269–70, 325–27
 rights and interests of, 6, 10, 25, 33–34, 44–45, 88, 168, 188–89, 191, 244, 291, 328
 rights and welfare of, 19, 20, 38–39, 75–76, 167, 183–84, 186–87, 191, 201–2, 290, 291, 293, 305, 313
 risks to, benefits to others and, 103, 293, 300–1
 special concern for basic interests of, 256–59
 standard of care, 30–31, 75
 trade-offs and incentives for, 313–15
 voluntary participation of, 161, 247
- study protocols, 7, 214, 219, 242, 322, 334–35, 336, 398–99
- surfactants, 78–79, 80, 81, 405–6
- Surfaxin, 78–80, 81, 91, 405–6
- systems of knowledge production, 23–24, 59, 247, 378
- Taylor, Charles, 140–43
- TC. *See* triggering condition
- template for the appeal to uncertainty, 177–79, 194–97, 220, 221, 250, 285, 290
 epistemic threshold of uncertainty, 197, 200
 equipoise and, 200–4
 fragility of individual uncertainty, 200–2, 204
 model of uncertainty, 197, 199
 normative basis for, 197–98
 whose uncertainty, 197, 198–99
- theoretical equipoise, 209, 210–11
- therapeutic warrant, 223–24, 258, 285, 286, 287–88
- trade-offs, incentives and, 313–15
- tragedy of the commons, 22–23, 301, 309–20, 323
- triggering condition (TC), 120, 121, 123, 124
 common good and, 120, 121, 123, 124, 125–27, 128, 129, 131, 138, 253–55
 lenient, 125–27, 128
 strict, 124, 128
- Tuskegee syphilis study, 6–7, 45n.7, 48–50, 62–63, 72, 305–6, 321
- uncertainty. *See also* template for the appeal to uncertainty
 component analysis and, 283–89
 epistemic humility and, 216–17
 equipoise and, 177–78, 204–5, 206–7, 208–10, 211, 215, 226
 in mind of individual clinician, 198, 199, 203, 204, 206, 215, 216, 219–20, 226, 268
 in model of single decision-maker, 274–76
 about outcomes, 325–26
 as practical test, within integrative approach, 263–69
 purely research-related risks and, 220–21, 222–23
 social model, of learning, uncertainty, and disagreement, 269–76
- uncertainty principle, 197–98, 208–11
- uncertainty regarding basic interests, 263n.5, 263–65, 289
- utilitarianism, 5, 19, 125–26, 127, 146, 244–45, 246–47
 consequentialism and, 184, 191
 institutional, 144–45, 147, 148
 objective, 146–47, 147n.22
 of research, 176–77, 183–85, 191–93, 201–2, 289, 292
 research risk and, 244, 290
- Varmus, Harold, 63, 72
- weak consequentialism, 97–98, 107
- Weijer, Charles, 197–98, 212–15, 216, 217–19, 264

- welfare
- aggregate, 124, 125–27, 129, 129n.11, 130
 - of community, 123, 125, 126, 129–30
 - concern for, 195, 250–51, 266–69, 272–73, 279–80
 - individual, 9, 20, 41, 55, 105, 125–26, 127, 129, 130, 144, 179, 244
 - interpersonal comparisons of, 145, 148, 293–95
 - intrapersonal comparisons of, 293–94
 - mutual benefits and, 14
 - norms of respect and, 90
 - objective utilitarianism on, 146–47, 147n.22
 - personal life plans and, 294
 - PPE on, 95–97, 101, 102, 103, 105, 106, 110
 - principle of utility on, 246, 247
 - research risks and, 289–90, 293–94
 - of research subjects, rights of violated, 35–36
 - of study participants, 19, 20, 38–39, 42, 75–76, 167, 183–84, 186–87, 191, 201–2, 290, 293
 - welfare consequentialism, 95–96, 100, 100n.13, 105n.14, 105–6, 107
 - Wenner, D. M., 105n.14, 387n.4, 387n.5, 388
 - Wertheimer, Alan, 13–15, 88–89, 92, 104–5, 160, 224, 226, 235–36, 331–32, 346–47, 350, 369, 389–90
 - Willowbrook, 6–7, 306n.4
 - World Medical Association, 37, 75, 181
 - yellow fever studies, in Havana, 37–38
 - 076 Protocol, 63–64, 66–67, 68–70, 71, 412, 420–21
 - zidovudine short-course trials, 60–84, 420